UK’s NICE Backs Two Microsphere Products For Liver Cancer But Says No To Another
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.
You may also be interested in...
Approval for Boston Scientific’s TheraSphere offers further access to the therapy that, until now, has only been available under a humanitarian device exemption.
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
Companies operating in New Zealand will have six months to transition to Medsafe’s updated code on good manufacturing practice.